



DAFTAR PUSTAKA

- Aguilar-Cazares, D., Chavez-Dominguez, R., Marroquin-Muciño, M., Perez-Medina, M., Benito-Lopez, J.J., Camarena, A., Rumbo-Nava, U., Lopez-Gonzalez, J.S. 2022. The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment. *Front. Endocrinol.* 13:929572.
- Ali, A.T., Al-Ani, O., Al-Ani, F. 2023. Epidemiology and risk factors for ovarian cancer. *Prz. Menopauzalny.* 2: 93–104.
- Alivameita, A. & Puspitasari. (2024) *Pemeriksaan Hematologi Rutin*. Sidoarjo: UMSIDA Press. ISBN: 978-623-464-098-4.
- Asher, V., Lee, J., Innamaa, A., Bali, A. 2011. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. *Clin. Transl. Oncol.*, 13(7):499–503.
- Austin, P.C. 2014. The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments. *Stat. Med.*, 33(7):1242–1258
- Bachmann, C., Bachmann, R., Fend, F., Wallwiener, D. 2016. Incidence and Impact of Lymph Node Metastases in Advanced Ovarian Cancer: Implications for Surgical Treatment. *J. Cancer*, 7(15):2241–2246.
- Bandera, E. V., Lee, V.S., Qin, B., Rodriguez-Rodriguez, L., Powell, C.B., Kushi, L.H. 2017. Impact of body mass index on ovarian cancer survival varies by stage. *Br. J. Cancer*, 117(2):282–289.
- Berek, J.S., Kehoe, S.T., Kumar, L., Friedlander, M. 2018. Cancer of the ovary, fallopian tube, and peritoneum. *Int. J. Gynecol. Obstet.*, 143:59–78.
- Brieger, K.K., Phung, M.T., Mukherjee, B., Bakulski, K.M., Anton-Culver, H., Bandera, E. V., Bowtell, D.D.L., Cramer, D.W., DeFazio, A., Doherty, J.A., Fereday, S., Fortner, R.T., Gentry-Maharaj, A., Goode, E.L., Goodman, M.T., Harris, H.R., Matsuo, K., Menon, U., Modugno, F., et al. 2022. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. *Cancer Epidemiol. Biomarkers Prev.*, 31(2):443–452.
- Budiana, I.N.G., Angelina, M., Pemayun, T.G.A. 2019. Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery. *J. Turkish-German Gynecol. Assoc.*, 20(1):47–54.
- Canreg.fkkmk (2022). Distribusi Kasus Kanker RSUP Dr. Sardjito/ FK-KMK UGM 2008-2019 [Cited 2023 Jun 09]. Available from : <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/rkbr-maret-2022/>
- Castaño, M., Tomás-Pérez, S., González-Cantó, E., Aghababayan, C., Mascarós-Martínez, A., Santonja, N., Herreros-Pomares, A., Oto, J., Medina, P., Götte, M., Mc Cormack, B.A., Marí-Alexandre, J., Gilabert-Estellés, J. 2023. Neutrophil Extracellular Traps and Cancer: Trapping Our Attention with Their Involvement in Ovarian Cancer. *Int. J. Mol. Sci.* 24(6):5995
- Chen, Y., Zhang, L., Liu, W.X., Liu, X.Y. 2015. Prognostic significance of preoperative anemia, leukocytosis and thrombocytosis in chinese women with epithelial ovarian cancer. *Asian Pacific J. Cancer Prev.*, 16(3):933–939.
- Chon, S., Lee, S., Jeong, D., Lim, S., Lee, K., Shin, J. 2021. Elevated platelet lymphocyte ratio is a poor prognostic factor in advanced epithelial ovarian



- cancer. *J. Gynecol. Obstet. Hum. Reprod.*, 50(6):101849.
- Dao, F., Schlappe, B.A., Tseng, J., Lester, J., Nick, A.M., Lutgendorf, S.K., Mcmeekin, S., Coleman, R.L., Moore, K.N., Karlan, B.Y., Sood, A.K., Levine, D.A. 2016. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. *Gynecol. Oncol.*, 141(2):260–263.
- Deng, F., Xu, X., Lv, M., Ren, B., Wang, Y., Guo, W., Feng, J., Chen, X. 2017. Age is associated with prognosis in serous ovarian carcinoma. *J. Ovarian Res.*, 10(1):36.
- Deng, K., Yang, C., Tan, Q., Song, W., Lu, M., Zhao, W., Lou, G., Li, Z., Li, K., Hou, Y. 2018. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. *Gynecol. Oncol.*, 150(3):460–465.
- Fagotti, A., Ferrandina, M.G., Vizzielli, G., Pasciuto, T., Fanfani, F., Gallotta, V., Margariti, P.A., Chiantera, V., Costantini, B., Gueli Alletti, S., Cosentino, F., Scambia, G. 2020. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer. *Int. J. Gynecol. Cancer*, 30(11):1657–1664.
- Fortner, R.T., Trewin-Nybråten, C.B., Paulsen, T., Langseth, H. 2023. Characterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway. *Int. J. Cancer*, 153(5):969–978.
- Gaitskell, K., Hermon, C., Barnes, I., Pirie, K., Floud, S., Green, J., Beral, V., Reeves, G.K. 2022. Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study. *Cancer Epidemiol.*, 76:102074.
- Ge, L.N., Wang, F. 2018. Prognostic significance of preoperative serum albumin in epithelial ovarian cancer patients: A systematic review and dose-response meta-analysis of observational studies. *Cancer Manag. Res.*, 10:815–825.
- Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata-Yanagimoto, M., Taniguchi, K. 2021. Inflammation-induced tumorigenesis and metastasis. *Int. J. Mol. Sci.* 22(11):5421.
- Himpunan Obstetri Ginekologi Indonesia. 2018 *Pedoman Nasional Pelayanan Kedokteran Kanker Ginekologi*.PNPK HOGI, Jakarta.
- Hirst, J., Crow, J., Godwin, A. 2018. Ovarian Cancer Genetics: Subtypes and Risk Factors. In: *Ovarian Cancer - From Pathog. to Treat. InTech.* 10:5772.
- Hu, D., Lin, Y., Liu, F., Zeng, L., Ouyang, X., Wang, K., Zheng, X., Huang, Q. 2018. Elevated Preoperative Platelet to Lymphocyte Ratio Indicates Poor Survival in Patient with Resected High-grade Serous Ovarian Carcinoma. *Clin Lab.* 6(28):1443-1449.
- Hu, Q., Hada, A., Han, L. 2020. Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer. *J. Ovarian Res.*, 13(1):78.
- Huang, H., Wu, K., Chen, L., Lin, X. 2021. Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors. *Int. J. Gen. Med.*, 14:10015–10022.
- Huang, J., Chan, W.C., Ngai, C.H., Lok, V., Zhang, L., Lucero-Prisno, D.E., Xu, W., Zheng, Z.J., Elcarte, E., Withers, M., Wong, M.C.S. 2022. Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. *Cancers (Basel)*, 14(9):2230.
- Huang, K., Xu, S., Wang, J., Ge, L., Xu, J., Jia, X. 2023. Combined use of CA125,



- neutrophil/lymphocyte ratio and platelet/lymphocyte ratio for the diagnosis of borderline and malignant epithelial ovarian tumors. *J. Ovarian Res.*, 16(1):37.
- Hufnagel, D.H., Cozzi, G.D., Crispens, M.A., Beeghly-Fadiel, A. 2020. Platelets, thrombocytosis, and ovarian cancer prognosis: Surveying the landscape of the literature. *Int. J. Mol. Sci.* 21(21):8169.
- Kwon, B.S., Jeong, D.H., Byun, J.M., Lee, T.H., Choi, K.U., Song, Y.J., Suh, D.S., Kim, K.H. 2018. Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma. *J. Cancer*, 9(7):1127–1134.
- Lee, Y.J., Chung, Y.S., Lee, J.Y., Nam, E.J., Kim, S.W., Kim, S., Kim, Y.T. 2019. Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer. *Cancer Med.*, 8(2):564–571.
- Lheureux, S., Braunstein, M., Oza, A.M. 2019. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. *CA. Cancer J. Clin.*, 69(4):280–304.
- Liu, H., Xu, Y., Ji, J., Dong, R., Qiu, H., Dai, X. 2020. Prognosis of ovarian clear cell cancer compared with other epithelial cancer types: A population-based analysis. *Oncol. Lett.*, 19(3):1947–1957.
- Liu, S., Wu, M., Wang, F. 2021. Research progress in prognostic factors and biomarkers of ovarian cancer. *J. Cancer.*, 12(13):3976–3996.
- Lukanović, D., Kobal, B., Černe, K. 2022. Ovarian Cancer: Treatment and Resistance to Pharmacotherapy. *Reprod. Med.*, 3(2):127–140.
- Ma, X.M., Sun, X., Yang, G.W., Yu, M.W., Zhang, G.L., Yu, J., Zhang, Y., Wang, X.M. 2017. The platelet-to-lymphocyte ratio as a predictor of patient outcomes in ovarian cancer: a meta-analysis. *Climacteric*, 20(5):448–455.
- Maleki, Z., Vali, M., Nikbakht, H.A., Hassanipour, S., Kouhi, A., Sedighi, S., Farokhi, R., Ghaem, H. 2023. Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis. *BMC Cancer*, 23(1):558.
- Marth, C., Abreu, M.H., Andersen, K.K., Aro, K.M., de Lurdes Batarda, M., Boll, D., Ekmann-Gade, A.W., Haltia, U.M., Hansen, J., Haug, A.J., Høgdall, C., Korach, J., Lassus, H., Lindemann, K., Van Nieuwenhuysen, E., Ottevanger, P.B., Polterauer, S., Schnack, T.H. 2022. Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial). *Cancer*, 128(16):3080–3089.
- Mehra, P., Aditi, S., Prasad, K.M., Bariar, N. k. 2023. Histomorphological Analysis of Ovarian Neoplasms According to the 2020 WHO Classification of Ovarian Tumors: A Distribution Pattern in a Tertiary Care Center. *Cureus*. 15(4) : 38273.
- Mleko, M., Pitynski, K., Pluta, E., Czerw, A., Sygit, K., Karakiewicz, B., Banas, T. 2021. Role of systemic inflammatory reaction in female genital organ malignancies – state of the art. *Cancer Manag. Res.* 13:5491–5508.
- Momenimovahed, Z., Tiznobaik, A., Taheri, S., Salehiniya, H. 2019. Ovarian cancer in the world: Epidemiology and risk factors. *Int. J. Womens. Health.* 11 : 287–299.
- Motohara, T., Masuda, K., Morotti, M., Zheng, Y., El-Sahhar, S., Chong, K.Y., Wietek, N., Alsaadi, A., Karaminejadranjbar, M., Hu, Z., Artibani, M., Gonzalez, L.S., Katabuchi, H., Saya, H., Ahmed, A.A. 2019. An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. *Oncogene*. 38(16) : 2885–2898.
- Prabowo, A., Tjokroprawiro, B.A., Utomo, B. 2022. Correlation between



- clinicopathological factors and clinical outcomes of recurrent epithelial ovarian cancer at a tertiary hospital in Surabaya, Indonesia. *Bali Med. J.*, 11(2):807–812.
- Ramón-Rodríguez, J., De-Armas-Conde, N., Jaén-Torrejimenó, I., Prada-Villaverde, A., Rojas-Holguín, A., López-Guerra, D., Blanco-Fernández, G. 2022. Prognostic value of pre-operative systemic immune-inflammation index and platelet to lymphocyte ratio in peritoneal carcinomatosis of ovarian origin. *Surg. Oncol.*, 42 : 101750.
- Raungkaewmanee, S., Tangjitgamol, S., Manusirivithaya, S., Srijaipracharoen, S., Thavaramara, T. 2012. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. *J. Gynecol. Oncol.*, 23(4):265–273.
- Rosales, C. 2018. Neutrophil: A cell with many roles in inflammation or several cell types? *Front. Physiol.* 9 : 113.
- Sambasivan, S. 2022. Epithelial ovarian cancer: Review article. *Cancer Treat. Res. Commun.* 33 : 100629.
- Santoiemma, P.P., Powell, D.J. 2015. Tumor infiltrating lymphocytes in ovarian cancer. *Cancer Biol. Ther.* 16 (6) : 807–820.
- Sastra, W.I.G., Aditya, P.P.K., Gradiyanto, O.E., Ketut, S. 2022. Predictive value of preoperative inflammatory markers and serum CA 125 level for surgical outcome in Indonesian women with epithelial ovarian cancer. *Cancer Biomarkers*, 34(1):123–129.
- Sheinenzon, A., Shehadeh, M., Michelis, R., Shaoul, E., Ronen, O. 2021. Serum albumin levels and inflammation. *Int. J. Biol. Macromol.*, 184:857–862.
- So, K.A., Hong, J.H., Jin, H.M., Kim, J.W., Song, J.Y., Lee, J.K., Lee, N.W. 2014. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: A retrospective cohort study. *Gynecol. Oncol.*, 132(3):551–555.
- Song, Q., Xu, S.X., Wu, J.Z., Ling, L., Wang, S., Shu, X.H., Ying, D.N., Pei, W.W., Wu, Y.C., Sun, S.F., Zhang, Y.N., Zhou, S.H., Shao, Z.Y. 2023. The preoperative platelet to neutrophil ratio and lymphocyte to monocyte ratio are superior prognostic indicators compared with other inflammatory biomarkers in ovarian cancer. *Front. Immunol.*, 14:1177403.
- Sun, H., Yan, L., Chen, H., Zheng, T., Zhang, Y., Wang, H. 2020. Development of a nomogram to predict prognosis in ovarian cancer: A SEER-based study. *Transl. Cancer Res.*, 9(10):5829–5842.
- Sysmex (2024). The white blood cell differential count application ‘DIFF’ [Cited 2024 Aug 07]. Available from : <https://www.sysmex-europe.com/academy/knowledge-centre/technologies/white-blood-cell-differential-count-application-diff/>.
- Team - RSUP dr. Sardjito Yogyakarta (2022). Mengenal Kanker Ovarium, The Silent Killer [Cited 2023 Sept 19]. Available from : https://yankes.kemkes.go.id/view_artikel/1043/mengenal-kanker-ovarium-the-silent-killer#:~:text=Menurut data Global Cancer Incidence,angka kematian mencapai 9.581 kasus.
- Tian, C., Song, W., Tian, X., Sun, Y. 2018. Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis. *Eur. J. Clin. Invest.*, 48(5) : 12917.
- Trifanescu, O.G., Mitrica, R.I., Gales, L.N., Marinescu, S.A., Motas, N., Trifanescu, R.A., Rebegea, L., Gherghe, M., Georgescu, D.E., Serbanescu, G.L., Bashar, H.H., Dragosloveanu, S., Cristian, D.A., Anghel, R.M. 2023. Validation of a New Prognostic Score in Patients with Ovarian Adenocarcinoma. *Med.*, 59(2) :



229.

- Wang, W., Gu, J., Liu, Y., Liu, X., Jiang, L., Wu, C., Liu, J. 2022. Pre-Treatment CRP-Albumin-Lymphocyte Index (CALLY Index) as a Prognostic Biomarker of Survival in Patients with Epithelial Ovarian Cancer. *Cancer Manag. Res.*, 14:2803–2812.
- Winarno, G.N.A., Pasaribu, M., Susanto, H., Nisa, A.S., Harsono, A.B., Yuseran, H., Suardi, D., Trianasari, N. 2021. The Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios in Predicting Response to Platinum-based Chemotherapy for Epithelial Ovarian Cancer. *Asian Pacific J. Cancer Prev.*, 22(5):1561–1566.
- Winarto, H., Welladatika, A., Habiburrahman, M., Purwoto, G., Kusuma, F., Utami, T.W., Putra, A.D., Anggraeni, T., Nuryanto, K.H. 2022. Overall Survival and Related Factors of Advanced-stage Epithelial Ovarian Cancer Patients Underwent Debulking Surgery in Jakarta, Indonesia: A Single-center Experience. *Open Access Maced. J. Med. Sci.*, 10:265–280.
- Winata, J., Laihada, B.J., M Wagey, F.M. 2023. Preoperative Platelet-Lymphocyte Ratio as a Prognostic Factor of Epithelial Ovarian Cancer Rasio Trombosit-Limfosit Pra Operasi sebagai Faktor Prognostik Epitel Kanker ovarium. *Obstet Gynecol.* (11) : 17.
- Zhang, C. long, Jiang, X. chen, Li, Y., Pan, X., Gao, M. qi, Chen, Y., Pang, B. 2023. Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR. *J. Ovarian Res.* 16:36
- Zhang, W. wei, Liu, K. jun, Hu, G. lin, Liang, W. jiang. 2015. Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients. *Tumor Biol.*, 36(11):8831–8837.
- Zhang, W., Zhang, Z., Qian, L. 2024. Prognostic and clinicopathological significance of C-reactive protein in patients with ovarian cancer: a meta-analysis. *World J. Surg. Oncol.*, 22(1) : 8.
- Zhou, Y., Wang, A., Sun, X., Zhang, R., Zhao, L. 2023. Survival prognosis model for elderly women with epithelial ovarian cancer based on the SEER database. *Front. Oncol.*, 13 : 1257615.